AMLX
insider transactionsAmylyx Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-412.5K
3.8K buy · 416.3K sell
Net value · 365d
-$5.7M
$51.3K in · $5.7M out
Sentiment · 365d
Net selling
1% buying · 99% selling
Open-market trades · 365d
18
3.8K buy · 416.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
24.4K sh
Own New
-
Grant·A
Director
$0
24.4K sh
Own New
-
Grant·A
Director
$0
24.4K sh
Own New
-
Grant·A
Director
$0
24.4K sh
Own New
-
Grant·A
Director
$0
24.4K sh
Own New
-
Buy·P
Director
$51.3K
3.8K sh · $13.51
Own +6%
-
Grant·A
Joshua B Cohen KEY
Co-Chief Executive Officer
$0
373.3K sh
Own New
-
Grant·A
Joshua B Cohen KEY
Co-Chief Executive Officer
$0
248.9K sh
Own +7%
-
Grant·A
Chief Legal Officer
$0
112.0K sh
Own New
-
Grant·A
Chief Legal Officer
$0
74.7K sh
Own +56%
-
Grant·A
James M Frates KEY
Chief Financial Officer
$0
144.0K sh
Own New
-
Grant·A
James M Frates KEY
Chief Financial Officer
$0
96.0K sh
Own +58%
-
Grant·A
Justin B. Klee KEY
Co-Chief Executive Officer
$0
373.3K sh
Own New
-
Grant·A
Justin B. Klee KEY
Co-Chief Executive Officer
$0
248.9K sh
Own +7%
-
Grant·A
Chief Medical Officer
$0
144.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
96.0K sh
Own +57%
-
Sell·S
Justin B. Klee KEY
Co-Chief Executive Officer
$423.8K
29.3K sh · $14.47
Own -1%
-
Sell·S
Joshua B Cohen KEY
Co-Chief Executive Officer
$424.1K
29.3K sh · $14.48
Own -1%
-
Sell·S
Chief Medical Officer
$94.2K
6.5K sh · $14.58
Own -4%
-
Sell·S
James M Frates KEY
Chief Financial Officer
$114.9K
7.9K sh · $14.52
Own -5%
-
Sell·S
Chief Legal Officer
$99.4K
6.8K sh · $14.52
Own -5%
-
Sell·S
Chief Legal Officer
$48.4K
3.4K sh · $14.14
Own -2%
-
Sell·S
James M Frates KEY
Chief Financial Officer
$52.1K
3.6K sh · $14.65
Own -2%
-
Sell·S
Joshua B Cohen KEY
Co-Chief Executive Officer
$227.6K
15.5K sh · $14.68
Own -0%
-
Sell·S
Chief Legal Officer
$50.5K
3.4K sh · $14.65
Own -2%
-
Sell·S
Justin B. Klee KEY
Co-Chief Executive Officer
$227.6K
15.5K sh · $14.69
Own -0%
-
Exercise·M
Joshua B Cohen KEY
Co-Chief Executive Officer
$0
2.8K sh
Own New
-
Sell·S
Joshua B Cohen KEY
Co-Chief Executive Officer
$27.3K
2.0K sh · $13.83
Own -0%
-
Exercise·M
Joshua B Cohen KEY
Co-Chief Executive Officer
$21.3K
2.8K sh · $7.57
Own +0%
-
Exercise·M
Justin B. Klee KEY
Co-Chief Executive Officer
$0
2.8K sh
Own New
-
Sell·S
Justin B. Klee KEY
Co-Chief Executive Officer
$27.7K
2.0K sh · $13.89
Own -0%
-
Exercise·M
Justin B. Klee KEY
Co-Chief Executive Officer
$21.6K
2.8K sh · $7.57
Own +0%
-
Exercise·M
Joshua B Cohen KEY
Co-Chief Executive Officer
$0
197.2K sh
Own New
-
Sell·S
Joshua B Cohen KEY
Co-Chief Executive Officer
$1.9M
136.2K sh · $13.59
Own -4%
-
Exercise·M
Joshua B Cohen KEY
Co-Chief Executive Officer
$1.5M
197.2K sh · $7.57
Own +6%
-
Exercise·M
Justin B. Klee KEY
Co-Chief Executive Officer
$0
197.2K sh
Own New
-
Sell·S
Justin B. Klee KEY
Co-Chief Executive Officer
$1.8M
136.2K sh · $13.58
Own -4%
-
Exercise·M
Justin B. Klee KEY
Co-Chief Executive Officer
$1.5M
197.2K sh · $7.57
Own +6%
-
Other·G
Director
$0
17.8K sh
Own -2%
-
Sell·S
James M Frates KEY
Chief Financial Officer
$37.0K
3.3K sh · $11.11
Own -2%
-
Sell·S
Joshua B Cohen KEY
Co-Chief Executive Officer
$85.6K
7.7K sh · $11.09
Own -0%
-
Sell·S
Justin B. Klee KEY
Co-Chief Executive Officer
$85.6K
7.7K sh · $11.09
Own -0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Bernhardt G Zeiher | Grant A | 24.4K | $0 |
| Jun 4, 2026 | Karen Firestone | Grant A | 24.4K | $0 |
| Jun 4, 2026 | Daphne Quimi | Grant A | 24.4K | $0 |
| Jun 4, 2026 | George M Milne JR | Grant A | 24.4K | $0 |
| Jun 4, 2026 | Paul R. Fonteyne | Grant A | 24.4K | $0 |
| May 21, 2026 | Karen Firestone | Buy P | 3.8K | $51.3K |
| Mar 5, 2026 | Joshua B Cohen KEY | Grant A | 373.3K | $0 |
| Mar 5, 2026 | Joshua B Cohen KEY | Grant A | 248.9K | $0 |
| Mar 5, 2026 | Gina Mazzariello | Grant A | 112.0K | $0 |
| Mar 5, 2026 | Gina Mazzariello | Grant A | 74.7K | $0 |
| Mar 5, 2026 | James M Frates KEY | Grant A | 144.0K | $0 |
| Mar 5, 2026 | James M Frates KEY | Grant A | 96.0K | $0 |
| Mar 5, 2026 | Justin B. Klee KEY | Grant A | 373.3K | $0 |
| Mar 5, 2026 | Justin B. Klee KEY | Grant A | 248.9K | $0 |
| Mar 5, 2026 | Camille L Bedrosian | Grant A | 144.0K | $0 |
| Mar 5, 2026 | Camille L Bedrosian | Grant A | 96.0K | $0 |
| Mar 2, 2026 | Justin B. Klee KEY | Sell S | 29.3K | $423.8K |
| Mar 2, 2026 | Joshua B Cohen KEY | Sell S | 29.3K | $424.1K |
| Mar 2, 2026 | Camille L Bedrosian | Sell S | 6.5K | $94.2K |
| Mar 2, 2026 | James M Frates KEY | Sell S | 7.9K | $114.9K |
| Mar 2, 2026 | Gina Mazzariello | Sell S | 6.8K | $99.4K |
| Feb 23, 2026 | Gina Mazzariello | Sell S | 3.4K | $48.4K |
| Feb 2, 2026 | James M Frates KEY | Sell S | 3.6K | $52.1K |
| Feb 2, 2026 | Joshua B Cohen KEY | Sell S | 15.5K | $227.6K |
| Feb 2, 2026 | Gina Mazzariello | Sell S | 3.4K | $50.5K |
| Feb 2, 2026 | Justin B. Klee KEY | Sell S | 15.5K | $227.6K |
| Jan 16, 2026 | Joshua B Cohen KEY | Exercise M | 2.8K | $0 |
| Jan 16, 2026 | Joshua B Cohen KEY | Sell S | 2.0K | $27.3K |
| Jan 16, 2026 | Joshua B Cohen KEY | Exercise M | 2.8K | $21.3K |
| Jan 16, 2026 | Justin B. Klee KEY | Exercise M | 2.8K | $0 |
| Jan 16, 2026 | Justin B. Klee KEY | Sell S | 2.0K | $27.7K |
| Jan 16, 2026 | Justin B. Klee KEY | Exercise M | 2.8K | $21.6K |
| Jan 15, 2026 | Joshua B Cohen KEY | Exercise M | 197.2K | $0 |
| Jan 15, 2026 | Joshua B Cohen KEY | Sell S | 136.2K | $1.9M |
| Jan 15, 2026 | Joshua B Cohen KEY | Exercise M | 197.2K | $1.5M |
| Jan 15, 2026 | Justin B. Klee KEY | Exercise M | 197.2K | $0 |
| Jan 15, 2026 | Justin B. Klee KEY | Sell S | 136.2K | $1.8M |
| Jan 15, 2026 | Justin B. Klee KEY | Exercise M | 197.2K | $1.5M |
| Jan 12, 2026 | George M Milne JR | Other G | 17.8K | $0 |
| Jan 6, 2026 | James M Frates KEY | Sell S | 3.3K | $37.0K |
| Jan 6, 2026 | Joshua B Cohen KEY | Sell S | 7.7K | $85.6K |
| Jan 6, 2026 | Justin B. Klee KEY | Sell S | 7.7K | $85.6K |
About AMLX insider trading
This page tracks insider transactions for Amylyx Pharmaceuticals, Inc. (AMLX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.